Repeated open application test with methyldibromo glutaronitrile, a multicentre study within the EECDRG.

Gruvberger, Birgitta; Andersen, K E; Brandão, F M; Bruynzeel, D P; Bruze, M; Frosch, P J; Goossens, A; Lahti, A; Maibach, H I; Menné, T; Orton, D; Seidenari, S

Published in:
Contact Dermatitis

DOI:
10.1111/j.0105-1873.2005.00481.x

2005

Link to publication

Citation for published version (APA):
Gruvberger, B., Andersen, K. E., Brandão, F. M., Bruynzeel, D. P., Bruze, M., Frosch, P. J., ... Seidenari, S. (2005). Repeated open application test with methyldibromo glutaronitrile, a multicentre study within the EECDRG. Contact Dermatitis, 52(1), 19-23. DOI: 10.1111/j.0105-1873.2005.00481.x

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Repeated open application test with methyldibromo glutaronitrile, a multicentre study within the EECDRG

B. GRUVBERGER1*, K. E. ANDERSEN2, F. M. BRANDÃO3, D. P. BRUYNZEEL4, M. BRUZE1, P. J. FROSCH5, A. GOOSSENS6, A. LAHTI7, H. I. MAIBACH8, T. MENNE9, D. ORTON10* and S. SEIDENARI11

1Department of Occupational and Environmental Dermatology, Malmö University Hospital, Malmö, Sweden, 2Department of Dermatology, Odense University Hospital, Odense, Denmark, 3Department of Dermatology, Hospital Garcia de Orta, Almanda, Portugal, 4Department of Dermatology, Free University Hospital, Amsterdam, The Netherlands, 5Department of Dermatology, Klinikum Dortmund and University of Witten/Herdecke, Dortmund, Germany, 6Department of Dermatology, University Hospital, K.U. Leuven, Belgium, 7Department of Dermatology, University of Oulu, Oulu, Finland, 8Department of Dermatology, UCSF, School of Medicine, San Francisco, CA, USA, 9Department of Dermatology, Gentofte Hospital, Copenhagen, Denmark, 10Department of Dermatology, Amersham General Hospital, Bucks, UK, and 11Department of Dermatology, University of Modena, Modena, Italy

Contact allergy to and allergic contact dermatitis from methyldibromo glutaronitrile (MDBGN) have frequently been reported. This study was initiated to help determine the optimal patch test preparation for MDBGN. In 51 patients with a doubtful or a positive patch test reaction to at least 1 of 4 test preparations with MDBGN in petrolatum at 1.0% w/w, 0.5%, 0.3% and 0.1%, a repeated open application test (ROAT) with moisturizers with and without MDBGN at 0.03% w/w was performed on the upper arms for 2 weeks. 18 of the 51 (35.3%) patients developed a positive ROAT. In all patients, there was a positive ROAT only to the moisturizer with MDBGN (P < 0.001). A statistically significant association was also found between the patch test reactivity (PTRL) and the outcome of the ROAT (P < 0.001). If only considering those with a PTRL above 0.3%, thus with negative or doubtful test reactions to 0.1% and 0.3%, there were still statistically significantly more patients with a positive ROAT to the moisturizer with MDBGN than to the moisturizer without MDBGN. The study demonstrates that patch testing with MDBGN at 0.3% and 0.1% will miss clinically relevant patch test reactions to MDBGN.

Key words: 1,2-dibromo-2,4-dicyanobutane; allergic contact dermatitis; CAS 35691–65–7; clinical relevance; Euxyl K400; methyldibromo glutaronitrile; moisturizer; patch testing; preservative; ROAT; Tekramer 38; usage test. © Blackwell Munksgaard, 2005.

Accepted for publication 22 October 2004

Contact allergy to the preservative methyldibromo glutaronitrile (MDBGN) (1,2-dibromo-2,4-dicyanobutane) has frequently been reported (1–8). Furthermore, allergic contact dermatitis from MDBGN in products, such as lotions, moist toilet paper, ultrasonic gels, natural products, eye gels, hair mousse, hair conditioners, sunscreen creams, protective creams, abrasive cleansers, work cream, detergents and glues, is likewise frequently reported (1, 9–24). Thus, MDBGN is a strong candidate to be introduced in the European standard patch test series (25). However, there has been no agreement on which test preparation to use to define contact allergy to MDBGN. As the purpose of patch testing with a standard test series is to find individuals with a clinically relevant contact allergy (25), 2 studies were initiated within the European Environmental and Contact Dermatitis Research Group (EECDRG) to help determine the optimal patch test preparation for MDBGN. The study with patch testing with various concentrations of MDBGN in petrolatum (petrol.) is also published in this issue of Contact Dermatitis (26), while the study presented here concerns repeated open application testing (ROAT) with moisturizers with and without MDBGN.

*Not members of the EECDRG.
Materials and Methods

Patients
From 10 European and 1 American patch test clinics during the period January 2002–June 2002, 51 patients with doubtful or positive reactions to at least 1 of the 4 simultaneously patch tested preparations with MDBGN in pet. at 1.0% w/w, 0.5%, 0.3% and 0.1% participated as a part of their individual investigation on the clinical relevance of the demonstrated or possible (doubtful reaction) contact allergy to MDBGN. 18 were males (mean age 53.4 year and range 27–71 year) and 33 were females (mean age 45.5 year and range 21–75 year).

Chemicals
MDBGN (Schülke and Mayr, Hamburg, Germany) from the same batch was used both for the patch testing with the 4 MDBGN preparations (26) and the ROAT. The pharmacy at the University Hospital in Malmö prepared 2 moisturizers which were identical (pet., sorbitan oleate and water) but for the preservative, 1 moisturizer was preserved with MDBGN at 0.03% w/w and the other with methyl paraben at 0.1% w/w and propyl paraben at 0.2% w/w.

Repeated open application test
The patients were instructed to use the moisturizers ×2 daily on the ventral aspects of the upper arms where a square measuring 5 × 5 cm was marked. Each patient received a pair of moisturizers with and without MDBGN. The pairs were numbered and the allocation of the moisturizer to be applied to the respective arm was done in a randomized way. The moisturizer to be applied to the right upper arm was marked with a blue tape, while a red tape was used for the moisturizer to be applied to the left arm. The patients were instructed to use an approximately 0.5-cm long string of the cream for each application (35 mg on 25 cm² = 1.4 mg/cm²). The study period was 2 weeks unless terminated earlier because of a positive ROAT or at the patient’s request. Inspection of the upper arms was done before the ROAT on the first day and then after 1 week and 2 weeks or at the request of the patient. An eczematous reaction was sought and considered to be positive if there was at least an erythematous infiltration with/without papules and/or vesicles covering at least 25% of the marked area (27). The patients were encouraged to continue the applications if there was only an erythematous reaction without infiltration or an eczematous reaction covering less than 25% of the area.

The code was broken after the individual termination, and the result of the ROAT could thus be used for the individual assessment of clinical relevance and as a basis for individual advice and preventive measures.

Statistical calculations
McNemar’s test was used to compare the number of patient arms with a positive ROAT for the moisturizers with and without MDBGN. This comparison was also done in those with a negative and/or doubtful patch test reaction to 0.1% and 0.3%, but a positive and/or doubtful reaction to 0.5% and 1.0%. The Spearman rank correlation test was used to investigate any association between the individual patch test reactivity (PTRL), defined as the lowest patch test concentration of MDBGN giving a positive reaction, i.e. at least a positive reaction according to ICDRG guidelines (28), and ROAT outcome, defined as the number of days until a positive ROAT appeared.

Results
18 of the 51 (35.3%) patients developed a positive response. Within the first week, 12 patients tested positively and 6 more patients tested positively the second week. In all patients, there was a positive ROAT only on 1 arm, and for all patients, this was the arm to which the MDBGN-containing moisturizer had been applied (P < 0.001). When the same comparison was made for those with a negative or doubtful patch test reaction to 0.1% and 0.3%, but a positive or doubtful reaction to 0.5% and 1.0%, there were statistically significantly more patients with a positive ROAT to the moisturizer with MDBGN than to the moisturizer without MDBGN (P < 0.05, McNemar’s test, one sided). 6 of those participating had at patch testing doubtful reactions to MDBGN (P < 0.05, McNemar’s test, one sided). 6 of those participating had at patch testing doubtful reactions to MDBGN at 0.3%, and in 1/3 a positive ROAT developed on the arm to which the moisturizer with MDBGN had been applied. Figure 1 shows the relationship between the outcome of ROAT with regard to the number of days until a positive ROAT appeared and the respective PTRL including those with doubtful reactions (P < 0.001), and Fig. 2 gives the distribution of positive and negative ROATs for the respective PTRLS including doubtful reactions.

Discussion
ROAT and other types of use tests can be used both in individual cases to help assess the clinical relevance of a positive or doubtful reaction to a sensitizer present in a product used by the patient
but with a negative product patch test and in
groups of hypersensitive patients undergoing
ROAT with a product containing the sensitizer.
For the individual ROAT, a positive test does not
say anything about the nature of the reaction, i.e.
the eczematous response can be either allergic or
irritant. On the other hand, when a ROAT is
scientifically designed and conducted, informa-
tion can be gained on both the general clinical
relevance and the nature of the ROAT reactions.

The present study gives information on the indi-
vidual clinical relevance in those testing positively
to ROAT and information on the general clinical
relevance of MDBGN positivity on patch testing,
as an instrument to help determine the optimal
patch test preparation for MDBGN. This study
demonstrates the clinical relevance of contact
allergy to MDBGN traced by patch testing with
pet. preparations with MDBGN at 0.1%–0.5%.
A dose–response relationship for PTRL and
ROAT outcomes (Fig. 1) was also demonstrated,
which gives further support to the significance of
the demonstrated positive patch test reactions.

The use of many different test preparations
with regard to vehicle and MDBGN concentra-
tions (1–3, 6, 7, 11, 15, 18, 23, 24, 29–34) and the
results of the EECDRG patch test study (26)
strongly indicate that patch test reactions to
MDBGN may be difficult to read. Therefore,
some dermatologists claim that MDBGN, besides
giving irritant reactions with an irritant morph-
ology, can give irritant reactions which are mis-
interpreted as allergic reactions, i.e. false-positive
reactions. In the case that a patch test reaction
representing a single application of a chemical is
false-positive, it is likely that multiple appli-
cations of the same chemical at a lower concen-
tration over an extended period of time would
result in a positive reaction of the same nature,
i.e. a false-positive reaction. When performing
ROAT in groups of individuals with contact
allergy, false-positive reactions and other irritant
reactions can be recognized by using appropriate
controls. As there was no control group in this
study, the positive ROATs could therefore be
false-positive. This interpretation, however,
seems highly unlikely and, furthermore, what is
more important, of only minute significance for
individual diagnostic and preventive measures
concerning allergic contact dermatitis/contact
dermatitis from MDBGN.

Actually, critical to the present possible in-
capacity always to unambiguously determine the
nature of positive patch tests (26) and ROATs to
MDBGN, besides legislative aspects, is how to
advise the positive reactors on which substances
to avoid. For allergenicity, but not for irritancy,
cross-reactivity is a phenomenon to consider,
which means that allergic persons should be
advised on potentially cross-reacting substances
to avoid relapses of allergic contact dermatitis.
However, cross-reactivity is not of major concern
for MDBGN, as there currently are virtually no
known chemically related substances in the envi-
ronment. Considering the fact that higher
MDBGN concentration can be present in leave-
on products, the possible significance of the use of
MDBGN-preserved leave-on products on damaged skin instead of healthy skin, and the significance of ROAT study periods exceeding 2 weeks (35, 36), makes it highly likely that the positive reactors to 1.0% at patch testing in this study would also have tested positively (statistically significant) with another ROAT study design, taking into account the above-mentioned factors.

This study demonstrates that a person who tests positively, independent of whether the positive patch test reactions to MDBGN at concentrations equal to or lower than 0.5% represent positive allergic or false-positive reactions, should avoid use of moisturizers preserved with MDBGN to avoid contact dermatitis relapses. This statement is supported by the fact that the used MDBGN concentration of 0.03%, chosen as chemical analysis of several hundred leave-on products on the Swedish market at the Department of Occupational and Environmental Dermatology in Malmö had shown 0.03% to be the mean concentration of MDBGN in those products preserved with this preservative (unpublished observation), is below the highest concentration that has been allowed in leave-on products (0.1% except for sunscreen products with 0.025%). Although a previous use test with a rinse-off product in MDBGN-hypersensitive individuals was negative (37), some of the authors of this article have for many year advised our individuals was negative (37), some of the authors of this article have for many year advised our patients with positive patch tests should avoid using products (0.1% except for sunscreen products with 0.025%). Although a previous use test with a rinse-off product in MDBGN-hypersensitive individuals was negative (37), some of the authors of this article have for many year advised our patients with positive patch tests should avoid using rinse-off products preserved with MDBGN. This advice is supported by the result of a recent study (38).

In summary, this study documents that patch testing with MDBGN at 0.3% and 0.1% will miss clinically relevant patch test reactions to MDBGN. With the present knowledge of contact allergy rates to MDBGN and clinical relevance, patients with positive patch tests should avoid MDBGN exposure, at least prolonged exposure occurring, for example, when using leave-on products. Furthermore, the circumstances of high and increasing European contact allergy rates to MDBGN, the reports on anecdotal cases with allergic contact dermatitis from MDBGN, as well as the ROAT results of this study merit legislative measures to confine or ban non-occupational, as well as occupational, exposure to MDBGN, particularly in leave-on products, to prevent sensitization to and elicitation from MDBGN in already sensitized persons. And, from July 2004, MDBGN has been banned in cosmetics of leave-on type, though patients may still now be exposed to MDBGN in leave-on products manufactured before that date, at concentrations up to 0.1%.

Acknowledgements
The study was financially supported by a grant from the National Skin Allergy Research Centre at Gentofte Hospital, Copenhagen, Denmark.

References


Address:
Birgitta Gruvberger
Department of Occupational and Environmental Dermatology
University Hospital
S-205 02 Malmö
Sweden
Tel: +46 40 33 17 59
Fax: +46 40 33 62 13
e-mail: birgitta.gruvberger@derm.mas.lu.se